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A B S T R A C T
The aim of this study was to delineate the associations between the tryptophan catabolite (TRYCAT) pathway and affective symptoms in schizophrenia. Towards this end we measured immunoglobulin (Ig)A and IgM responses to relatively noxious TRYCATs, namely quinolinic (QA), xanthurenic (XA), picolinic (PA) acid and 3-OHkynurenine (3HK), and generally protective TRYCATs, namely anthranilic (AA) and kynurenic (KA) acid in 80 patients with schizophrenia and 40 healthy controls. The Hamilton Rating Scale for Depression (HDRS) and anxiety (HAMA), Young Mania Rating Scale (YMRS) as well as the Positive and Negative Symptoms Scale of Schizophrenia (PANSS) were measured.
Depression, anxiety and hypomanic as well as negative and positive symptoms were associated with increased IgA responses to PA. Increased IgA responses to XA were associated with anxiety, hypomanic and negative symptoms. Moreover, depressive, anxiety, hypomanic and negative symptoms were characterized by increased IgA responses to the noxious (XA + 3HK + QA + PA)/protective (AA + KA) TRYCAT ratio. All symptom dimensions were associated with increased IgM responses to QA, while depressive, anxiety, positive and negative symptoms were accompanied by lowered IgM responses to 3HK. Hypomanic symptoms were additionally accompanied by lowered IgM responses to AA, and negative symptoms by increased IgM responses to KA.
In conclusion, both shared and distinct alterations in the activity of the TRYCAT pathway, as well as its regulatory factors and consequences, may underpin affective and classical psychotic symptoms of schizophrenia. Increased mucosa-generated production of noxious TRYCATs, especially PA, and specific changes in IgMmediated regulatory activities may be associated with the different symptom dimensions of schizophrenia.
Introduction
Schizophrenia is a complex psychiatric disorder, which is classically characterized by different symptom dimensions, including negative (e.g. anhedonia, social inhibition, alogia, flattened affect, loss of interest and anhedonia), positive (e.g. hallucinations, delusions, hostile and aggressive behaviors and disorganized thinking), neurocognitive (e.g. disorders in executive functions, sustained attention, and speed of processing) and affective symptoms (Andreasen and Olsen, 1982; Emsley et al., 1999; Lieberman et al., 1991; Mellor, 1991; Lindenmayer et al., 1995; Van den Oord et al., 2006; Kim et al., 2012) . Many patients with schizophrenia experience affective symptoms, including depressive and anxiety symptoms, which may be secondary to positive and negative symptoms of schizophrenia (Emsley et al., 1999; Kirschner et al., 2016) and/or part of an early developmental etiology (Anderson et al., 2013) . Previous work established that depression and anxiety
